Bank Hapoalim BM Sells 600 Shares of Novo Nordisk A/S (NYSE:NVO)

Bank Hapoalim BM lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,110 shares of the company’s stock after selling 600 shares during the period. Bank Hapoalim BM’s holdings in Novo Nordisk A/S were worth $1,085,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the second quarter worth approximately $25,000. Orion Capital Management LLC bought a new stake in Novo Nordisk A/S in the first quarter worth approximately $26,000. Gilliland Jeter Wealth Management LLC lifted its stake in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its stake in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.3 %

NVO traded down $2.62 during trading on Thursday, hitting $110.62. 1,493,433 shares of the company’s stock were exchanged, compared to its average volume of 4,330,806. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The stock has a market cap of $496.41 billion, a P/E ratio of 38.78, a PEG ratio of 1.48 and a beta of 0.42. The business’s 50 day moving average is $125.25 and its two-hundred day moving average is $131.06. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s payout ratio is 24.66%.

Analyst Ratings Changes

NVO has been the subject of several research analyst reports. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.